Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] LigaChem Biosciences (141080) – iM Securities | Clinical Data · Pipeline Progress · Tech Transfer / 2026-05-21 Research
  • [Research] SK hynix (000660 / SKHY) – Meritz | ADR Listing · Valuation Discount · Re-rating / 2026-04-23 Research
  • [Research] Samsung SDI (006400) – Kyobo Securities | AI Data Center BBU · Direct CSP Channels · 1Q Earnings Beat / 2026-04-29 Research
  • [Research] LigaChem Biosciences (141080) – Mirae Asset Securities | Clinical Milestones · Commercialization Potential · Platform PoC / 2025-05-23 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · SOX Inclusion · HBM Pricing / 2026-06-25 Research
  • [Research] Samsung SDI (006400) – Hana Securities | North America JV Resolution · ESS Line Conversion · Earnings Estimate Upgrades / 2026-08-12 Research
  • [Research] Celltrion (068270) – DS Investment & Securities | 2Q26 Re: Steep Growth Exceeds Expectations · New Biosimilars Surge · Large-Cap Top Pick / 2026-07-28 Research
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | MLCC Price Hikes · Server Product Mix · Target Price Revision / 2026-07-31 Research

[Research] LIG D&A (079550) – Daishin Securities | 1Q26 Review · Earnings Surprise · Export Diversification / 2026-05-08

Posted on May 8, 2026August 21, 2026 By ksb220805@gmail.com

Brokerage : Daishin Securities

Analyst : Jeonghwan Cho, CFA

Investment Rating : BUY (Maintain)

Target Price : KRW 1,100,000 (Maintain)

Core Momentum : Strong 1Q26 operating profit surprise driven by high-margin UAE Cheongung-II maintenance and spare parts, with accelerated growth post-2027 anchored by three Middle Eastern contracts

1. [Valuation & Key Financial Metrics]

  • Investment Rating & Target Price: Rating BUY (Maintain), 6-Month Target Price KRW 1,100,000 (Maintain), Current Price KRW 866,000 (As of May 7, 2026), Upside Potential 27.0%
  • Valuation Methodology: Target price derived by applying a Target P/E multiple of 31.5x (a 25% premium to the global defense/radar peer 24MF P/E) to the 2027 estimated controlling net profit of KRW 770 Billion (Target Market Cap KRW 24,267 Billion based on 22,000 Thousand shares)
  • Financial Forecasts & Historicals:
    • 2024A: Revenue KRW 3,276 Billion, Operating Profit KRW 230 Billion, Pre-tax Profit KRW 210 Billion, Total Net Profit KRW 217 Billion, Controlling Net Profit KRW 222 Billion, EPS KRW 10,106, P/E 18x, BPS KRW 56,248, P/B 15x, ROE 17.5%
    • 2025A: Revenue KRW 4,307 Billion, Operating Profit KRW 321 Billion, Pre-tax Profit KRW 278 Billion, Total Net Profit KRW 237 Billion, Controlling Net Profit KRW 253 Billion, EPS KRW 11,516, P/E 28x, BPS KRW 67,077, P/B 13x, ROE 16.1%
    • 2026F: Revenue KRW 5,607 Billion, Operating Profit KRW 466 Billion, Pre-tax Profit KRW 459 Billion, Total Net Profit KRW 366 Billion, Controlling Net Profit KRW 385 Billion, EPS KRW 17,507, P/E 49x, BPS KRW 79,901, P/B 11x, ROE 20.8%
    • 2027F: Revenue KRW 7,124 Billion, Operating Profit KRW 807 Billion, Pre-tax Profit KRW 850 Billion, Total Net Profit KRW 725 Billion, Controlling Net Profit KRW 770 Billion, EPS KRW 35,017, P/E 25x, BPS KRW 105,725, P/B 8x, ROE 31.2%
    • 2028F: Revenue KRW 7,589 Billion, Operating Profit KRW 833 Billion, Pre-tax Profit KRW 868 Billion, Total Net Profit KRW 740 Billion, Controlling Net Profit KRW 786 Billion, EPS KRW 35,733, P/E 24x, BPS KRW 131,046, P/B 7x, ROE 25.5%
  • Stock Metrics: KOSPI 7,490.05pt, Market Cap KRW 19,052 Billion, Market Cap Weight 0.35%, Capital Stock KRW 110 Billion, 52-Week High/Low KRW 1,020,000 / KRW 336,500, 120-Day Avg Daily Trading Value KRW 216.7 Billion, Foreign Ownership 23.67%, Major Shareholders LIG & 8 affiliated parties (38.21%), National Pension Service (9.7%)

2. [Market Opportunities & Business Outlook]

  • 1Q26 Earnings Review:
    • Consolidated revenue reached KRW 1,167.9 Billion (+28.7% YoY) and operating profit recorded KRW 171.1 Billion (+56.1% YoY, OPM 14.7%).
    • Revenue was slightly below internal estimates (KRW 1,189.0 Billion), while operating profit significantly beat both forecasts (KRW 126.0 Billion) and market consensus.
    • Export mix stood at 34.7%, with profitability driven by high-margin UAE Cheongung-II maintenance and spare parts revenues. In addition to KRW 170.0 Billion from UAE Cheongung-II, other export revenues of ~KRW 230.0 Billion were primarily driven by missile systems across the Middle East and other client nations. Ghost Robotics posted an operating loss of KRW 13.0 Billion.
  • 2026 Earnings Profile:
    • Export revenues are projected to increase in 2H26 driven by UAE and Saudi Arabia Cheongung-II deliveries.
    • However, full-year operating margins are expected to trend downward in 2H due to seasonal provisions associated with new domestic contract awards concentrated in 4Q26.
  • Long-Term Growth & Pipeline Diversification:
    • Simultaneous revenue recognition from UAE, Saudi Arabia, and Iraq contracts starting post-2027 is projected to propel 2027 export revenue to KRW 3.1 Trillion (+68.9% YoY), raising export contribution to 43.3%.
    • Product portfolio is expected to broaden from Cheongung-II to advanced systems including L-SAM and LAMD.

Editor’s Comment (Perspective)

The covering analyst views LIG D&A not through the lens of near-term second-half margin moderation driven by domestic contract provisioning, but as a premier defense contractor entering a structural earnings compounding phase supported by acute global interceptor shortages and secured Middle East backlogs. This perspective emphasizes the demonstrated profitability from high-margin maintenance revenues (overcoming slight top-line shortfall in 1Q), the jump in export mix to 43.3% by 2027, and long-term portfolio diversification into next-generation systems like L-SAM and LAMD over quarterly delivery seasonality.

To verify whether this investment thesis continues to materialize, primary focus should be directed toward the execution pace of UAE and Saudi Arabia Cheongung-II deliveries in 2H26, the scale of domestic project provisions in 4Q26, and the simultaneous revenue recognition across UAE, Saudi Arabia, and Iraq contracts post-2027 alongside international pipeline expansion for L-SAM and LAMD. These operational milestones can be monitored through upcoming quarterly earnings releases, corporate IR disclosures, contract award filings, and official periodic reports.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Defense

Post navigation

Previous Post: [Research] Celltrion (068270) – IBK Securities | New Biosimilar Mix Expansion · Operating Leverage · H2 Margin Expansion / 2026-05-07
Next Post: [Research] LIG D&A (079550) – Hana Securities | 1Q26 Earnings Beat · Backlog Re-rating · High-margin Follow-on Services / 2026-05-08

Related Posts

  • [Research] LIG D&A (079550) – Daishin Securities | 2Q26 Review · Backlog Realization · Export Margin Expansion / 2026-08-10 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | SDC Stake Monetization Pursuit · North America ESS & Europe EV Order Acceleration · Operating Profit Turnaround / 2026-04-29 Research
  • [Research] Samsung Electro-Mechanics (009150) – SK Securities | Global Tier-1 Multiples · Passive-Substrate Synergy · Embedded & Si-Cap / 2026-05-26 Research
  • [Research] Samsung Electro-Mechanics (009150) – Daishin Securities | Supply Shortage · High-End Mix · Earnings Upward Revisions / 2026-07-07 Research
  • [Research] LigaChem Biosciences (141080) – Mirae Asset Securities | Clinical Readouts · Pipeline Valuation · SOTP / 2026-01-26 Research
  • [Research] Samsung Electro-Mechanics (009150) – DS Investment & Securities | MLCC Price Leverage · Capacity Cannibalization · Earnings Upward Revisions / 2026-07-31 Research
  • [Research] Hanwha Ocean (042660) – DS Investment & Securities | Merchant Vessel Profitability · High-Price Mix · MASGA Beneficiary / 2026-07-28 Research
  • [IR] Samsung Electro-Mechanics (009150) – Q3 2025 Earnings Presentation / 2025-10-29 IR Room
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Memory Pricing · LTA · Supply Tightness / 2026-04-23 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Memory Pricing Resilience · Earnings Visibility · Valuation Appeal / 2026-04-01 Research
  • [Research] Alteogen (196170) – Daishin Securities | Key US Patent Risks Significantly Eased · New Licensing Catalysts · Keytruda SC Milestones / 2026-06-02 Research
  • [Research] SK hynix (000660 / SKHY) – Yuanta | Memory Pricing · Long-Term Contracts · Earnings Stability / 2026-04-23 Research
  • [Research] Celltrion (068270) – Shinhan Securities | North American New Product Penetration · 2030 Pipeline · New Drug Cycle / 2026-07-28 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Memory ASP · Earnings Upgrades · Valuation Appeal / 2026-03-16 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme